News

Progress Software Robustly Reports Q3 Financial Success

Progress Software Robustly Reports Q3 Financial Success

Progress Software Reports Strong Financial Results for Third Quarter

Progress Software (NASDAQ: PRGS), a leading provider of AI-powered digital experience and infrastructure software, has released its financial results for the recently concluded fiscal third quarter, which ended on August 31, 2025. The results reflect a robust performance amidst a competitive landscape.

Key Financial Highlights

The quarter showcased remarkable growth metrics. Revenue reached $250 million, indicating a 40% increase year-over-year when measured in actual currency, and a 38% increase based on constant currency.

Annualized Recurring Revenue (ARR) surged to $849 million, marking a significant year-over-year growth of 47% on a constant currency basis. The operating margin stood at 18%, while non-GAAP operating margins soared to 40%.

Earnings Performance

The diluted earnings per share (EPS) was reported at $0.44, down from $0.65 during the same quarter last year, reflecting a 32% decrease. Conversely, the non-GAAP diluted EPS improved to $1.50, an increase of 19% compared to $1.26 in the prior year's quarter.

CEO's Commentary on Performance

Yogesh Gupta, the CEO of Progress Software, expressed immense pride in the company’s third-quarter performance. He highlighted that net retention remained stable at 100%, showcasing efficiency and customer loyalty. Gupta also mentioned that the integration of ShareFile has positively impacted both top and bottom lines, underscoring the importance of strategic investments in AI capabilities.

Operational and Financial Metrics

Further financial highlights from the quarter indicate that cash and cash equivalents were at $99 million, with days sales outstanding increasing to 55 days compared to 45 days the previous year. In a proactive move, the Board of Directors approved an increase in the share repurchase authorization by $200 million, raising its total to $242.2 million.

Favorable Guidance for Future Performance

Looking towards the end of the fiscal year ending November 30, 2025, Progress Software has updated its guidance. The forecast includes a revenue target of $975 to $981 million along with a projected diluted EPS of $1.38 to $1.45. The company is poised for continued fiscal strength, as reflected in the positive outlook presented by its leadership.

Challenges and Strategic Focus

Despite facing various challenges, including market competition and fluctuating currency exchange rates, Progress Software is strategically leveraging its resources. The company continues to enhance its software offerings and streamline operations, ensuring that it remains at the forefront of technological advancement.

Investor Relations and Future Prospects

The investor contact for Progress Software, Michael Micciche, emphasizes the need for transparency and communication with stakeholders. With the recent robust results, the company aims to build investor confidence and foster relationships based on mutual growth and success. Progress Software’s commitment to innovation hints at exciting developments on the horizon.

Frequently Asked Questions

What are the recent earnings figures reported by Progress Software?

Progress Software reported total revenue of $250 million, with an annualized recurring revenue (ARR) of $849 million for the third quarter.

How has the CEO addressed the company’s performance?

CEO Yogesh Gupta expressed pride in the company’s performance, citing stable net retention and significant revenue and earnings growth.

What is the company’s outlook for the rest of the fiscal year?

Progress Software has increased its revenue guidance to a range of $975 to $981 million and expects diluted earnings per share between $1.38 and $1.45.

What strategic investments is the company making?

Progress is investing in AI capabilities and enhancing integration strategies, particularly through the ShareFile platform.

How is Progress maintaining investor relationships?

The investor relations team is focusing on transparency and promoting ongoing communication to build confidence among stakeholders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading